<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01467180</url>
  </required_header>
  <id_info>
    <org_study_id>1490</org_study_id>
    <secondary_id>CIV-11-06-000843</secondary_id>
    <nct_id>NCT01467180</nct_id>
  </id_info>
  <brief_title>Myoglobin Removal by High Cut-off CVVHD</brief_title>
  <acronym>HicoRhabdo</acronym>
  <official_title>Myoglobin Reduction by High Cut-off (HCO) Continuous Veno- Venous Hemodialysis (CVVHD) in Patients With Rhabdomyolysis and an Increased Risk for Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gambro Dialysatoren GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A high cut-off dialyzer (septeX) is tested for the removal of myoglobin which is not
      efficiently removed by standard high flux dialysis membranes. Hypothesis: The high cut-off
      dialyzer (septeX) can remove 2-fold more efficiently myoglobin from the circulation of
      Rhabdomyolysis patients as by conventional treatment with standard high flux dialyzer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Excess myoglobin in the circulation is a causative pathogenetic factor of rhabdomyolysis
      associated with acute kidney injury (AKI). The rapid elimination of myoglobin by standard
      dialysis membranes is limited to its molecular weight of 17.8kDa, although some removal can
      be achieved when a convective therapy is applied.

      Significant clearance for myoglobin has been reported for high flux membranes from &lt; 8 mL/min
      (5) up to 22 mL/h (CVVH) (10) and for high cut-off (HCO) membranes a mean clearance rate of
      36.2 mL/min in HD mode (7) and 39.2 mL/h in CVVH mode (5). The use of high cut-off (HCO)
      continuous veno- venous hemodialysis (CVVHD) may constitute a novel therapeutic strategy for
      effectively reduction of myoglobin in the patient's serum to ameliorate the course of AKI.

      Previously, a case study of the removal of myoglobin by HCO-CVVH in one single patient with
      severe rhabdomyolysis was published.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myoglobin plasma level</measure>
    <time_frame>24h</time_frame>
    <description>Two fold- increased reduction of myoglobin plasma level in favor of the HCO CVVHD group compared with standard therapy group (HF-CVVH and fluid therapy, respectively) after 48 hours treatment time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>eGFR</measure>
    <time_frame>at 3 and 6 month after treatment</time_frame>
    <description>Estimation of kidney function by estimated glomerular filtration rate (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay (days)and Duration of ICU stay (days)</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of dialysis dependence (days)</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diuresis / oliguria (&lt;0.5 ml/kg/12h)/ anuria</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient survival</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Rhabdomyolysis</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>HCO CVVHD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment of rhabdomyolysis pts with septeX dialyzer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HF CVVH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment of rhabdomyolysis pts with standard high flux dialyzer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>septeX</intervention_name>
    <description>continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h</description>
    <arm_group_label>HCO CVVHD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HF CVVH</intervention_name>
    <description>continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h</description>
    <arm_group_label>HF CVVH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute Rhabdomyolysis

          -  placed central venous catheter

          -  Indication for RRT due to Serum CK level &gt; 5000 u/L

          -  Age ≥ 18 years

          -  Signed ICF

        Exclusion Criteria:

          -  End stage CKD (dialysis dependent) renal failure before manifestation of
             rhabdomyolysis

          -  Pregnancy or lactation

          -  Palliative treatment

          -  Participation in other clinical studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinik für Anästhesiologie, Intensivmedizin, Uni-Klinikum</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2011</study_first_submitted>
  <study_first_submitted_qc>November 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>septeX</keyword>
  <keyword>CVVH</keyword>
  <keyword>CVHD</keyword>
  <keyword>myoglobin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Rhabdomyolysis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

